ECS Botanics Holdings Past Earnings Performance
Past criteria checks 4/6
ECS Botanics Holdings has been growing earnings at an average annual rate of 50.4%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 65.1% per year. ECS Botanics Holdings's return on equity is 6.8%, and it has net margins of 9.6%.
Key information
50.4%
Earnings growth rate
54.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 65.1% |
| Return on equity | 6.8% |
| Net Margin | 9.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Lacklustre Performance Is Driving ECS Botanics Holdings Ltd's (ASX:ECS) 26% Price Drop
Nov 11
There's No Escaping ECS Botanics Holdings Ltd's (ASX:ECS) Muted Earnings Despite A 38% Share Price Rise
Sep 27ECS Botanics Holdings Ltd's (ASX:ECS) Shares Lagging The Market But So Is The Business
Aug 12There Is A Reason ECS Botanics Holdings Ltd's (ASX:ECS) Price Is Undemanding
Apr 03ECS Botanics Holdings Ltd's (ASX:ECS) Share Price Could Signal Some Risk
Sep 06ECS Botanics Holdings (ASX:ECS) Is In A Good Position To Deliver On Growth Plans
Feb 24Revenue & Expenses Breakdown
How ECS Botanics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 20 | 2 | 6 | 0 |
| 31 Mar 24 | 20 | 2 | 6 | 0 |
| 31 Dec 23 | 20 | 2 | 6 | 0 |
| 30 Sep 23 | 18 | 1 | 6 | 0 |
| 30 Jun 23 | 15 | 0 | 5 | 0 |
| 31 Dec 22 | 10 | 2 | 2 | 0 |
| 30 Sep 22 | 7 | 1 | 2 | 0 |
| 30 Jun 22 | 5 | 0 | 2 | 0 |
| 31 Mar 22 | 5 | -3 | 4 | 0 |
| 31 Dec 21 | 3 | -4 | 4 | 0 |
| 30 Sep 21 | 2 | -4 | 4 | 0 |
| 30 Jun 21 | 1 | -4 | 4 | 0 |
| 31 Mar 21 | 1 | -4 | 4 | 0 |
| 31 Dec 20 | 1 | -4 | 4 | 0 |
| 30 Sep 20 | 1 | -4 | 3 | 0 |
| 30 Jun 20 | 1 | -5 | 2 | 0 |
| 31 Dec 19 | 0 | -4 | 1 | 0 |
| 30 Sep 19 | 0 | -2 | 1 | 0 |
| 30 Jun 19 | 0 | -1 | 0 | 0 |
Quality Earnings: ECS has a high level of non-cash earnings.
Growing Profit Margin: ECS's current net profit margins (9.6%) are higher than last year (3.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ECS has become profitable over the past 5 years, growing earnings by 50.4% per year.
Accelerating Growth: ECS's earnings growth over the past year (289.8%) exceeds its 5-year average (50.4% per year).
Earnings vs Industry: ECS earnings growth over the past year (289.8%) exceeded the Pharmaceuticals industry 46.5%.
Return on Equity
High ROE: ECS's Return on Equity (6.8%) is considered low.